A multiple ascending dose, phase1b study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of lesigercept, a long-acting IgETrap-Fc fusion protein, in participants with atopy or allergic diseases
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2026.117275 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift International Immunopharmacology, 2026. Verfasst von You Sook Cho und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Asan Medical Center, Ulsan University College of Medicine, Songpa-gu, Seoul 05505, the Republic of Korea. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Anti-Allergic Agents, Dermatitis, Atopic, Hypersensitivity. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Health and Welfare, Yuhan, Korea Health Industry Development Institute.
Abstract (Originalsprache)
BACKGROUND: Lesigercept (also known as YH35324) has shown favorable safety, dose-proportional pharmacokinetics (PK), and sustained suppression of serum free immunoglobulin E (IgE) after single dosing in participants with atopy. We examined these outcomes following repeated dosing in participants with atopy or allergic diseases. METHODS: In this phase 1b study, healthy adults who had atopy, with or without mild allergic diseases, and had serum total IgE level ≥30 IU/mL (Cohorts 1-4), and adults with moderate-to-severe atopic dermatitis (Cohort 5), were enrolled and randomized. Cohorts 1, 2, and 4 received lesigercept (0.75 mg/kg at 2-week intervals [Q2W], 3 mg/kg at 4-week intervals [Q4W], and 6 mg/kg at 8-week intervals [Q8W], respectively) or placebo (6:1). Cohort 3 received lesigercept (6 mg/kg Q4W), placebo, or omalizumab (300 mg Q4W) (6:1:6). Cohort 5 received lesigercept (6 mg/kg Q2W) or placebo (2,1). All cohorts were followed for 141 days. RESULTS: Across Cohorts 1-4, participants received lesigercept (n = 25), omalizumab (n = 6), or placebo (n = 5); Cohort 5 received lesigercept (n = 6) or placebo (n = 3). Treatment-emergent adverse events (TEAEs) occurred in 15 participants in Cohorts 1-4 (lesigercept: 36.0%, omalizumab: 50.0%, placebo: 60.0%) and in 5 participants in Cohort 5 (lesigercept: 83.3%, placebo: 0%). No drug-related grade ≥3 or serious TEAEs, discontinuation, death, or anaphylaxis occurred. Lesigercept exposure (Cmax and AUClast) increased dose-dependently, and serum free IgE levels were suppressed in all lesigercept groups, with longer median durations below 25 ng/mL than placebo (10-29 versus 0 days). CONCLUSION: Lesigercept exhibited favorable safety, predictable PK, and durable serum free IgE suppression after repeated dosing, supporting further clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergy, Asan Medical Center, Ulsan University College of Medicine, Songpa-gu, Seoul 05505, the Republic of Korea.
- Department of Allergy and Clinical Immunology, Ajou University Hospital, Yeongtong-gu, Suwon-si, Gyeonggi-do 16499, the Republic of Korea.
- Department of Internal Medicine, The Catholic University Medical College of Korea, Seocho-gu, Seoul 06591, the Republic of Korea.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam-si, Gyeonggi-do 13620, the Republic of Korea.
- Department of Dermatology, Nowon Eulji Medical Center, Eulji University, Nowon-gu, Seoul 01830, the Republic of Korea.
- Department of Dermatology, Korea University College of Medicine, Seongbuk-gu, Seoul 02841, the Republic of Korea.
Förderung
- Ministry of Health and Welfare
- Yuhan
- Korea Health Industry Development Institute
Zitieren
APA
Cho, Y. S., Ye, Y. M., Lee, S. Y., Kim, S. H., Han, T. Y., Ahn, H. H., Park, Y. L., Lee, Y. W., Ertle, J. M., Cho, H. J., Sim, S., Kim, B., Lee, J., Lee, J., Kim, S. K., Lee, J. H., Jang, M. H., & Park, H. S. (2026). A multiple ascending dose, phase1b study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of lesigercept, a long-acting IgETrap-Fc fusion protein, in participants with atopy or allergic diseases. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.117275
Vancouver
Cho YS, Ye YM, Lee SY, Kim SH, Han TY, Ahn HH, et al. A multiple ascending dose, phase1b study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of lesigercept, a long-acting IgETrap-Fc fusion protein, in participants with atopy or allergic diseases. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.117275
BibTeX
@article{Cho2026,
author = {Cho, You Sook and Ye, Young Min and Lee, Sook Young and Kim, Sae-Hoon and Han, Tae Young and Ahn, Hyo Hyun and Park, Young Lip and Lee, Yang Won and Ertle, Judith Maria and Cho, Hyeon-Ju and Sim, Sujin and Kim, Bomin and Lee, Jungwook and Lee, Jieon and Kim, Su Kyung and Lee, Ji-Hyung and Jang, Myoung Ho and Park, Hae-Sim},
title = {A multiple ascending dose, phase1b study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of lesigercept, a long-acting IgETrap-Fc fusion protein, in participants with atopy or allergic diseases},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2026.117275}
}
EUVIMED